The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations.
 
Victor Moreno
No Relationships to Disclose
 
Yohann Loriot
No Relationships to Disclose
 
Begona Pérez Valderrama
No Relationships to Disclose
 
Carmen Beato
No Relationships to Disclose
 
Yann-Alexandre Vano
No Relationships to Disclose
 
Mark T. Fleming
No Relationships to Disclose
 
Ignacio Duran
No Relationships to Disclose
 
Salvatore Siena
No Relationships to Disclose
 
Jaszianne A. Tolbert
No Relationships to Disclose
 
Anne OHagan
No Relationships to Disclose
 
Sydney Akapame
No Relationships to Disclose
 
Yvonne Y. Lau
No Relationships to Disclose
 
Lionnel Geoffrois
No Relationships to Disclose
 
Scott T. Tagawa
No Relationships to Disclose
 
Begona Mellado
No Relationships to Disclose
 
Arlene O. Siefker-Radtke
No Relationships to Disclose